Novo Nordisk (NVO.US) and Valo Health have expanded their collaboration to develop new cardio-metabolic medicines, investing a massive $4.6 billion in joint research.
AInvestWednesday, Jan 8, 2025 8:40 am ET
1min read
NVO --
VALU --

Danish pharma giant Novo Nordisk (NVO.US) and artificial intelligence biotech company Valo Health announced on Wednesday to expand their collaboration, aiming to accelerate the development of new therapies for heart metabolic diseases. Under the latest agreement, the two sides will jointly advance 20 new drug projects covering cardiovascular diseases, obesity, and type 2 diabetes, with Valo potentially receiving milestone payments totaling about $4.6 billion and other development funding and royalties.

The initial agreement reached in 2023 focused on the cardiovascular disease field, with Novo Nordisk and Valo agreeing to jointly advance up to 11 drug projects. At that time, Valo had the right to receive up to $2.7 billion in milestone payments. The revised agreement significantly expanded the collaboration scope, adding nine new projects focused on obesity, type 2 diabetes, and cardiovascular diseases, among others.

As part of the agreement, Valo will also receive $190 million in total funding from Novo Nordisk, including upfront payments, equity investments, and potential near-term milestone payments.

Novo Nordisk's scientific head Marcus Schindler expressed his high satisfaction with the progress of the collaboration in its first year and emphasized the expectation of expanding the collaboration scope and focusing on more disease areas.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.